"Our debt on the books stands at Rs 101 crore at present, out of which Rs 40 crore will get reduced from the IPO. Also, it could be totally debt free in a couple of years," L Rathi, MD, Advanced Enzymes Technologies told ET Now So we expect the debt to be less than Rs 50 crore going forward. The top 10 customers accounted for 41.5 per cent of the company's total revenues in FY16 on a consolidated basis. "The company has no listed peer in India while global enzymes leader Novozymes trades at a PE ratio of 35.5.

Source: Economic Times July 22, 2016 06:51 UTC